Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion. [50] In April 2016, the Los Angeles Times reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 million, making him one of the highest paid ...
Here are some of the most anticipated IPOs for 2024. ... But 2022 was the worst year for IPOs since at least 2010, so last year’s strong rebound performance comes off a much-reduced base, ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
For premium support please call: 800-290-4726 more ways to reach us